Industry ownership intelligence

Medical Devices insider conviction

Executive and director activity assessed across 83 companies for breadth, transaction quality, clustering, freshness, and directional conviction.

49/100

Balanced insider tape

83/100 confidence
Level
Industry
Evidence window
Latest 90 days
Named insiders
628
Latest evidence
24 Jul 2026

Capital positioning read

Balanced insider tape

Acquisition and disposal evidence is mixed after low-information compensation and derivative activity is separated out.

Wait for clearer clustering

Evidence in favour

  • 135 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 628 named insiders rather than one filing source.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction49Balanced insider tape
Confidence83Deep evidence
Controlled events528directional common-share events
Company breadth83represented companies
Acquisition value$15.8Mnormalized amount
Disposal value$232.1Mnormalized amount

Flow regime

Twelve-week filing pressure

Shows the cadence and balance of the full filing tape.

30818 May
15825 May
30901 Jun
16008 Jun
15715 Jun
7922 Jun
11129 Jun
7006 Jul
4213 Jul
1920 Jul
027 Jul
003 Aug
AcquisitionsDisposalsScore 49 · Confidence 83

Relative positioning

Industry peer map

Current score with confidence.

Directional balance

Controlled event mix

25.6%acquisition
Acquisition events
135
Disposal events
393
Net value
-$216.3M

Evidence quality

What the filings represent

Common equity1080
Equity compensation310
Options and derivatives223
Other securities10

Decision makers

Role participation

Director867
Other executive302
CEO and chair158
Finance leadership129
Other or unspecified111
Large holder56

Quality controls

Evidence usability

Normalized values
35%
Priced common share
34%
Named insiders
628
Controlled events
528

Auditable evidence

Latest Medical Devices filings

Showing 631 to 660 of 1623.

BFLYButterfly Network Inc
CASHMAN, STEVEChief Business Officer
DisposalCommon equity
$1.4MDirectional evidence
MDTMedtronic PLC
KIIL, HARRY SKIPEVP & President Cardiovascular
DisposalCommon equity
$318.6KDirectional evidence
MDTMedtronic PLC
KIIL, HARRY SKIPEVP & President Cardiovascular
DisposalCommon equity
$18.3KDirectional evidence
PRCTProcept Biorobotics Corp
TEMPLIN, BARRY LEVP, Chief Technology Officer
DisposalCommon equity
$10.2KDirectional evidence
PRCTProcept Biorobotics Corp
WATERS, KEVINEVP, CFO
DisposalCommon equity
$10.2KDirectional evidence
PRCTProcept Biorobotics Corp
NOURI, ALALEHEVP, CLO, CORP. SEC.
DisposalCommon equity
$8.1KDirectional evidence
SERASera Prognostics Inc
LAWRENCE, SANDRA AJDirector
DisposalCommon equity
$3.4KDirectional evidence
IRIXIRIDEX Corporation
DIZON, ROMEO RChief Financial Officer
AcquisitionCommon equity
$2.7KDirectional evidence
QDELQuidel Corporation
BUECHLER, KENNETH FDirector
AcquisitionCommon equity
Not reportedContext evidence
QDELQuidel Corporation
BUECHLER, KENNETH FDirector
DisposalEquity compensation
Not reportedContext evidence
QDELQuidel Corporation
BUECHLER, KENNETH FDirector
DisposalEquity compensation
Not reportedContext evidence
QDELQuidel Corporation
BUECHLER, KENNETH FDirector
AcquisitionCommon equity
Not reportedContext evidence
QDELQuidel Corporation
MICHAEL, EDWARD L.Director
AcquisitionCommon equity
Not reportedContext evidence
QDELQuidel Corporation
MICHAEL, EDWARD L.Director
DisposalEquity compensation
Not reportedContext evidence
QDELQuidel Corporation
MICHAEL, EDWARD L.Director
DisposalEquity compensation
Not reportedContext evidence
QDELQuidel Corporation
MICHAEL, EDWARD L.Director
AcquisitionCommon equity
Not reportedContext evidence
QDELQuidel Corporation
POLAN, MARY LAKE PH DDirector
AcquisitionCommon equity
Not reportedContext evidence
QDELQuidel Corporation
POLAN, MARY LAKE PH DDirector
DisposalEquity compensation
Not reportedContext evidence
QDELQuidel Corporation
POLAN, MARY LAKE PH DDirector
DisposalEquity compensation
Not reportedContext evidence
QDELQuidel Corporation
POLAN, MARY LAKE PH DDirector
AcquisitionCommon equity
Not reportedContext evidence
QDELQuidel Corporation
WIDDER, KENNETH JDirector
DisposalEquity compensation
Not reportedContext evidence
QDELQuidel Corporation
WIDDER, KENNETH JDirector
DisposalEquity compensation
Not reportedContext evidence
QDELQuidel Corporation
WIDDER, KENNETH JDirector
AcquisitionCommon equity
Not reportedContext evidence
QDELQuidel Corporation
WIDDER, KENNETH JDirector
AcquisitionCommon equity
Not reportedContext evidence
GMEDGlobus Medical
DAVIDAR, DAVID DDirector
DisposalOptions and derivatives
Not reportedContext evidence
INGNInogen Inc
BOEHNLEIN, GLENN SDirector
AcquisitionCommon equity
Not reportedContext evidence
INGNInogen Inc
JAMALI, VAFADirector
AcquisitionCommon equity
Not reportedContext evidence
INGNInogen Inc
KING, KEVIN MDirector
AcquisitionCommon equity
Not reportedContext evidence
INGNInogen Inc
LADONE, MARY KAYDirector
AcquisitionCommon equity
Not reportedContext evidence
INGNInogen Inc
MORA, ELIZABETHDirector
AcquisitionCommon equity
Not reportedContext evidence

Group-level method

Breadth before headline value

Company breadth

A sector or industry score must be supported across companies. One very large filing cannot manufacture broad conviction.

Economic duplicates

Matching company, date, side, security class, share count, and value records are consolidated for the directional calculation.

Evidence hierarchy

Priced common-share activity determines direction. Compensation and derivative records are mapped separately so ownership mechanics remain visible.

Positioning use

The score identifies where insider alignment merits research or where disposal concentration needs review. Price, trend, valuation, and portfolio risk still decide positioning.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context